Opus Genetics (IRD) said Friday that it has priced a $20 million underwritten public offering, as well as a concurrent private placement for gross proceeds of $1.5 million.
The ophthalmic biotechnology company said there will also be up to $21.4 million in additional proceeds when the warrants are exercised. The offerings are expected to close Monday.
Opus said the net proceeds will be used to fund the clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as general corporate purposes and working capital.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。